|
Dr. Thomas Hecht
MD, Chairman of the Board of Directors at Delenex since inception and Head of HHC consulting in Küssnacht, Switzerland. He was previously Vice President Marketing at Amgen Europe, Lucerne, Switzerland. A seasoned manager and industry professional, he has held various positions of increasing responsibility in clinical development, medical affairs and marketing at Amgen between 1989 and 2002. Prior to joining the biopharmaceutical industry, he certified in internal medicine and served as Co-Head of the Program for Bone Marrow Transplantation, University of Freiburg, Germany.
Today, he provides services to the pharmaceutical industry in clinical development/marketing and licensing strategies through HHC, a biopharmaceutical consulting company founded in 2002. He also serves as Chairman of the Boards of Affimed Therapeutics AG, Cytos Biotechnology AG and of the supervisory counsil of SuppreMol GmbH. In addition, he serves on the Board of Cell Medica Ltd. In 2009, with the acquisition by Alcon, he stepped down from the Chairmanship of ESBATech AG.
|